Key Takeaways:
Apimeds Pharmaceuticals US Inc. reached a settlement with Inscobee, clearing the way for its merger with MindWave Innovations and a $100 million PIPE financing.
"The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement of Lōkahi Therapeutics," the company said in a statement.
The agreement resolves all outstanding disputes from the December 1, 2025, merger agreement. The deal also provides for the formation of a new wholly-owned subsidiary, "Newco," and the advancement of the Apitox program under Lōkahi Therapeutics.
APUS common stock is expected to resume trading on the NYSE American on May 5, 2026. The resolution and funding are expected to positively impact the stock by removing significant uncertainty for investors.
Under the settlement, Lōkahi Therapeutics will secure the rights to the Apitox program, a non-opioid, biologic-based therapy for pain management. Lōkahi will pay $4 million to Apimeds and receive a $2.2 million credit facility to support the program's development. Apimeds will retain a 49 percent stake in Lōkahi, with 51 percent distributed as directed by former CEO Erik Emerson.
A new subsidiary, Newco, will be formed within seven business days, receiving ten percent of the net proceeds from the financing arrangement. The remaining ninety percent will be allocated to MindWave. Newco is expected to be spun off from Apimeds within twelve months.
The settlement provides Apimeds with a clear path to execute its strategic merger and secures crucial funding for its development pipeline. Investors will now watch for the successful closing of the financing and the subsequent trading resumption to gauge market confidence.
This article is for informational purposes only and does not constitute investment advice.
